2024-09-24 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis:

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and commercializes life-changing medicines for serious diseases.

**Performance Analysis:**

**1. Performance vs. S&P 500 (VOO):**
* **Cumulative Return:**  REGN: 117.31%, VOO: 132.53%
* **Divergence:**  REGN has underperformed VOO by 15.22%.
* **Relative Divergence:**  Currently at 55.6%, which means that REGN is performing lower than VOO by 55.6% compared to its historical performance range.

**2. Recent Price Action:**
* **Closing Price:** $1145.03
* **5-Day Moving Average:** $1147.38
* **20-Day Moving Average:** $1163.53
* **60-Day Moving Average:** $1117.09
* **Analysis:** The stock is currently trading below its 5-day and 20-day moving averages, indicating a short-term downtrend. However, it is above its 60-day moving average, suggesting a potential upward momentum in the long term.

**3. Technical Indicators:**
* **RSI:** 39.39 - Indicates the stock is in the oversold territory, suggesting potential rebound.
* **PPO:** -0.39 - Negative value indicates a bearish signal.
* **Delta_Previous_Relative_Divergence:** -10.81 - Negative value indicates a recent short-term downtrend.
* **Expected_Return:** 17.62% - Suggests a potential for a high return over the next 5 years, given current investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

* **Analysis:** The most recent earnings (2024-08-01) came in above expectations.  Regeneron has consistently demonstrated growth in revenue and EPS, indicating strong financial performance.

**5. Overall Analysis:**
* While Regeneron has underperformed the S&P 500 in the recent past, it is currently in the oversold territory based on RSI and has demonstrated strong financial performance with consistent revenue and EPS growth.  
* The recent downtrend may be a short-term dip with the potential for a rebound in the future.
* While a 17.62% expected return is positive, investors should consider the current market conditions and individual risk tolerance when making investment decisions.

**Recommendation:**
Regeneron Pharmaceuticals Inc. (REGN) holds a strong position within the biotech sector and shows potential for future growth. While it has underperformed the S&P 500 recently, its recent earnings beat and positive technical indicators suggest a potential rebound. Investors who are comfortable with the inherent risk of the biotechnology industry may consider REGN for their portfolio. However, it is essential to conduct thorough research and consult with a financial advisor before making any investment decisions. 
